Stay updated on A(B)VD+Nivolumab in Frontline for HL Clinical Trial
Sign up to get notified when there's something new on the A(B)VD+Nivolumab in Frontline for HL Clinical Trial page.

Latest updates to the A(B)VD+Nivolumab in Frontline for HL Clinical Trial page
- CheckyesterdayChange DetectedA new revision label Revision: v3.3.4 was added, replacing Revision: v3.3.3. This appears to be a minor site maintenance update and does not affect study information.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedLocations sections for Michigan, New Jersey, and New York have been added, and the previous separate location blocks for these states have been removed. This update corresponds to revision v3.3.3 of the page.SummaryDifference0.4%

- Check45 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 in the page footer.SummaryDifference0.0%

- Check52 days agoChange DetectedPublications section wording updated to indicate PubMed-sourced items are automatically filled. The page now shows a Last Update Posted (Estimated) date and a Revision: v3.3.1.SummaryDifference0.3%

- Check59 days agoChange DetectedThe notice about government funding and NIH operating status has been removed. This does not affect the study details, eligibility criteria, or outcomes listed for NCT03033914.SummaryDifference0.3%

- Check73 days agoChange DetectedThe two screenshots show no significant changes to core trial information or page structure. Any minor differences do not affect the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to A(B)VD+Nivolumab in Frontline for HL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the A(B)VD+Nivolumab in Frontline for HL Clinical Trial page.